drugset
Drugs / VPM1002
last change Dec 2025 re-read 9 days ago

VPM1002

also known as Mycobacterium bovis BCG ΔureC::hly Hm(R) · Mycobacterium bovis rBCGΔureC::hly

Vaccine

Developed for
tuberculosis · COVID-19 · respiratory tract infectious disorder
Investigated by
Serum Life Science Europe GmbH · Serum Institute of India Pvt. Ltd. · University of Stellenbosch · Children's Infectious Diseases Clinical Research Unit (KID-CRU) · Children's Infectious Diseases Clinical Research Unit (KID-CRU), South Africa · Desmond Tutu TB Centre
+16 more · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · FGK Clinical Research GmbH · Farmovs-Parexel Bloemfontein, Republic of South Africa (Clinical Site) · HJ-CTC George, RSA (Statistics & Report) · HJ-CTC George, South Africa · International Maternal Pediatric Adolescent AIDS Clinical Trials Group · Max Planck Institute for Infection Biology · National Institute of Allergy and Infectious Diseases (NIAID) · National Institute of Mental Health (NIMH) · South African Tuberculosis Vaccine Initiative · The Respiratory and Meningeal Pathogens Research Unit (RMPRU) · Triclinium Clinical Trial Project Management (Pty) Ltd. · Triclinium Johannesburg, RSA (Monitoring and Overall Management of the study) · Triclinium Johannesburg, South Africa · University Health Network, Toronto · Verity Pharmaceuticals Inc.

Trials 9

today NCT05539989 · Ph 1/2 NCT04351685 · Ph 3 NCT04439045 · Ph 3 NCT04435379 · Ph 3 NCT03152903 · Ph 2/3 NCT02391415 · Ph 2 NCT01479972 · Ph 2 NCT01113281 · Ph 1 NCT00749034 · Ph 1
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT01113281 Apr → Dec 2010 tuberculosis Serum Life Science Europe GmbH Completed No outcome recorded
Phase 1 NCT00749034 Sep 2008 → Dec 2009 tuberculosis Serum Life Science Europe GmbH Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT05539989 Dec 2025 HIV infectious disease, tuberculosis International Maternal Pediatric Adolescent AIDS Clinical Trials Group Withdrawn No outcome recorded
Phase 22 trials · 1 met primary
Phase 2 NCT02391415 Jun 2015 → Nov 2017 tuberculosis Serum Institute of India Pvt. Ltd. Completed Met primary
Phase 2 NCT01479972 Nov 2011 → Nov 2012 tuberculosis Serum Life Science Europe GmbH Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT03152903 Dec 2017 → Dec 2023 tuberculosis Serum Institute of India Pvt. Ltd. Completed No outcome recorded
Phase 33 trials
Phase 3 NCT04351685 Nov 2020 → Oct 2024 tuberculosis Serum Institute of India Pvt. Ltd. Completed No outcome recorded
Phase 3 NCT04439045 Jun 2020 → Sep 2021 COVID-19 University Health Network, Toronto Completed No outcome recorded
Phase 3 NCT04435379 Jun 2020 → Oct 2021 respiratory tract infectious disorder Serum Life Science Europe GmbH Completed No outcome recorded
Comparator or background therapy1 trial
Phase 3 NCT04387409 Comparator May 2020 → Apr 2021 respiratory tract infectious disorder Serum Life Science Europe GmbH Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as VPM1002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02391415 ↗
9

NCT01113281 ↗

NCT00749034 ↗

NCT04439045 ↗

NCT04435379 ↗

NCT05539989 ↗

NCT01479972 ↗

NCT03152903 ↗

NCT04387409 ↗

NCT04351685 ↗
Known as Mycobacterium bovis BCG ΔureC::hly Hm(R) “received one intradermal dose of VPM1002 (Mycobacterium bovis BCG ΔureC::hly Hm(R)) or BCG” PMID 23290835 ↗ Jan 2013
Known as Mycobacterium bovis rBCGΔureC::hly “Mycobacterium bovis rBCGΔureC::hly (VPM1002) vaccination” NCT05539989 ↗
Modality Vaccine “a recombinant BCG vaccine candidate” PMID 23290835 ↗ Jan 2013
Route Other “administered intradermally” NCT04351685 ↗